Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

The Defense Health Agency is soliciting quotes from pharmaceutical manufacturers for nine specific agents—including Atoncy for ADHD, Baxfendy for mineralocorticoid antagonism, duloxetine as an SNRI, Filkri as a filgrastim, Hepcludex for hepatitis D, Lynavoy for gastrointestinal use, Veppanu for breast cancer, Xocova as a COVID antiviral, and Xtoro as a quinolone antibiotic—to support Uniform Formulary placement decisions. Awards may include Uniform Formulary Blanket Purchase Agreements and Additional Discount Program agreements based on clinical and cost-effectiveness evaluations by the Pharmacy and Therapeutics Committee. Pharmaceutical companies supplying these agents, particularly those compliant with Trade Agreements Act requirements, are eligible to respond.